Abstract:Aims: Breast cancer (BC) is the most frequently occurring cancer in women worldwide. BC patients are often diagnosed at advanced stages which are characterized by low survival rates. Distant metastasis is considered a leading cause of mortalities among BC patients. Epithelial-to-mesenchymal transition (EMT) is a transdifferentiation program that is necessary for cancer cells to acquire metastatic potential. In the last decade, long noncoding RNAs (lncRNAs) proved their significant contribution to different hallmarks of cancer, including EMT and metastasis. The primary aim of our review is to analyze recent studies concerning the molecular mechanisms of lncRNAs implicated in EMT regulation in BC. Materials and methods: We adopted a comprehensive search on databases of PubMed, Web of Science, and Google Scholar using the following keywords: lncRNAs, EMT, breast cancer, and therapeutic targeting. Key findings: The different roles of lncRNAs in the mechanisms and signaling pathways governing EMT in BC were summarized. LncRNAs could induce or inhibit EMT through WNT/β-catenin, transforming growth factor-β (TGF-β), Notch, phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), signal transducer and activator of transcription 3 (STAT3), and nuclear factor kappa B (NF-κB) pathways as well as via their interaction with histone modifying complexes and miRNAs. Significance: LncRNAs are key regulators of EMT and BC metastasis, presenting potential targets for therapeutic interventions. Further research is necessary to investigate the practical application of lncRNAs in clinical therapeutics.

LncRNAs and the Cancer Epigenome: Mechanisms and Therapeutic Potential

Dysregulation Of Long Non-Coding Rna In Breast Cancer: An Overview Of Mechanism And Clinical Implication

Long Noncoding RNAs as New Architects in Cancer Epigenetics, Prognostic Biomarkers, and Potential Therapeutic Targets

Role of Cytoplasmic Lncrnas in Regulating Cancer Signaling Pathways

Exosomal Long Non-Coding RNAs: Biological Properties and Therapeutic Potential in Cancer Treatment

Long Noncoding RNA: Its Partners and Their Roles in Cancer

The Role of Long Non-Coding RNAs in the Tumor Immune Microenvironment

LncRNAs As Epigenetic Regulators of Epithelial to Mesenchymal Transition in Pancreatic Cancer

Long Non-Coding RNAs: an Emerging Powerhouse in the Battle Between Life and Death of Tumor Cells

Long Non-Coding RNAs, Nuclear Receptors and Their Cross-Talks in Cancer—Implications and Perspectives

Non-coding RNAs, epigenetics, and cancer: tying it all together

An immunotherapeutic approach to decipher the role of long non-coding RNAs in cancer progression, resistance and epigenetic regulation of immune cells

Coding roles of long non-coding RNAs in breast cancer: Emerging molecular diagnostic biomarkers and potential therapeutic targets with special reference to chemotherapy resistance

Lncrna Regulation: New Frontiers In Epigenetic Solutions To Drug Chemoresistance

Long Non-Coding RNAs as Regulators of Interactions between Cancer-Associated Fibroblasts and Cancer Cells in the Tumor Microenvironment

Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy

LncRNA Regulation: New Frontiers in Epigenetic Solutions to Drug Chemoresistance.

Emerging role of RNA modification and long noncoding RNA interaction in cancer

Long Non-Coding RNAs as Epigenetic Regulators of Immune Checkpoints in Cancer Immunity

lncRNAs and Cyclin-Dependent Kinases: Unveiling Their Critical Roles in Cancer Progression

Long noncoding RNAs as regulators of epithelial mesenchymal transition in breast cancer: A recent review